Germline BRCA1/2 alterations in the Homologous Recombination (HR) pathway are
considered as main susceptibility biomarkers to Hereditary Breast and Ovarian Cancers …

The anti-cancer efficacy of anti-malignancy therapies is related to DNA damage. However,
DNA damage-response mechanisms can repair DNA damage, failing anti-tumor therapy …

Colorectal cancer (CRC) is estimated as the third most incident cancer and second in
mortality worldwide. Moreover, CRC metastasis reduces patients' survival rates. Thus, the …

Pancreatic ductal adenocarcinoma (PDAC) is associated with one of the most unfavorable
prognoses across all malignancies. In this review, we investigate the role of inhibitors …

Drug resistance is a significant challenge in oncology and is driven by various mechanisms,
among which a crucial role is played by enhanced DNA repair. Thus, targeting DNA damage …

Background Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are approved for the
treatment of various solid tumors. In gastric cancer, genes commonly harbor mutations in the …

Simple Summary Histone and DNA methylations are widely studied epigenetic marks in
gastric cancer. Methylation is involved in DNA damage repair (DDR) and can also regulate …

Gemcitabine (GEM) is commonly chosen for treating pancreatic cancer. However, its use is
limited by toxicity. Earlier in vitro studies with GEM in combination with Bromelain (Brom) …

This study aimed to identify BRCA1/2 mutational patterns in the tissue and blood of Egyptian
colorectal cancer (CRC) patients and to study the possible correlation of this mutational …

Gastric cancer is a global health burden with high incidence and mortality rates with more
than 1 million new cases, primarily gastric adenocarcinomas, and 768 000 deaths according …